1
|
Dalin F, Nordling Eriksson G, Dahlqvist P, Hallgren Å, Wahlberg J, Ekwall O, Söderberg S, Rönnelid J, Olcén P, Winqvist O, Catrina SB, Kriström B, Laudius M, Isaksson M, Halldin Stenlid M, Gustafsson J, Gebre-Medhin G, Björnsdottir S, Janson A, Åkerman AK, Åman J, Duchen K, Bergthorsdottir R, Johannsson G, Lindskog E, Landin-Olsson M, Elfving M, Waldenström E, Hulting AL, Kämpe O, Bensing S. Clinical and Immunological Characteristics of Autoimmune Addison Disease: A Nationwide Swedish Multicenter Study. J Clin Endocrinol Metab 2017; 102:379-389. [PMID: 27870550 DOI: 10.1210/jc.2016-2522] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 10/07/2016] [Indexed: 11/19/2022]
Abstract
CONTEXT Studies of the clinical and immunological features of autoimmune Addison disease (AAD) are needed to understand the disease burden and increased mortality. OBJECTIVE To provide upgraded data on autoimmune comorbidities, replacement therapy, autoantibody profiles, and cardiovascular risk factors. DESIGN, SETTING, AND PARTICIPANTS A cross-sectional, population-based study that included 660 AAD patients from the Swedish Addison Registry (2008-2014). When analyzing the cardiovascular risk factors, 3594 individuals from the population-based survey in Northern Sweden, MONICA (monitoring of trends and determinants of cardiovascular disease), served as controls. MAIN OUTCOME MEASURES The endpoints were the prevalence of autoimmune comorbidities and cardiovascular risk factors. Autoantibodies against 13 autoantigens were determined. RESULTS The proportion of 21-hydroxylase autoantibody-positive patients was 83%, and 62% of patients had ≥1 associated autoimmune diseases, more frequently coexisting in females (P < 0.0001). AAD patients had a lower body mass index (P < 0.0001) and prevalence of hypertension (P = 0.027) compared with controls. Conventional hydrocortisone tablets were used by 89% of the patients, with a mean dose of 28.1 ± 8.5 mg/d. The mean hydrocortisone equivalent dose normalized to the body surface was 14.8 ± 4.4 mg/m2/d. A greater hydrocortisone equivalent dose was associated with a greater incidence of hypertension (P = 0.046). CONCLUSIONS Careful monitoring of AAD patients is warranted to detect associated autoimmune diseases. Contemporary Swedish AAD patients did not have an increased prevalence of overweight, hypertension, type 2 diabetes mellitus, or hyperlipidemia. However, high glucocorticoid replacement doses could be a risk factor for hypertension.
Collapse
Affiliation(s)
- Frida Dalin
- Centre for Molecular Medicine, Department of Medicine (Solna)
- Science for Life Laboratory, Department of Medical Sciences, and
| | | | - Per Dahlqvist
- Department of Public Health and Clinical Medicine and
| | - Åsa Hallgren
- Centre for Molecular Medicine, Department of Medicine (Solna)
| | - Jeanette Wahlberg
- Division of Endocrinology, Department of Medical and Health Sciences, Faculty of Health Sciences, and
| | - Olov Ekwall
- Department of Pediatrics, Institute of Clinical Sciences
| | | | | | - Per Olcén
- Department of Laboratory Medicine and
| | - Ola Winqvist
- Translational Immunology, Department of Medicine (Solna), and
| | - Sergiu-Bogdan Catrina
- Department of Molecular Medicine and Surgery, and
- Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Karolinska Institutet, Stockholm SE-17176, Sweden
| | - Berit Kriström
- Institution of Clinical Science, Pediatrics, Umeå University, Umeå SE-90736, Sweden
| | - Maria Laudius
- Department of Public Health and Clinical Medicine and
| | | | | | - Jan Gustafsson
- Women's and Children's Health, Uppsala University, Uppsala SE-75236, Sweden
| | | | - Sigridur Björnsdottir
- Department of Molecular Medicine and Surgery, and
- Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Karolinska Institutet, Stockholm SE-17176, Sweden
| | - Annika Janson
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm SE-17176, Sweden
| | | | - Jan Åman
- Department of Pediatrics, Faculty of Medicine and Health, Örebro University, Örebro SE-70281, Sweden
| | - Karel Duchen
- Division of Pediatrics, Department of Clinical and Experimental Medicine, Linköping University, Linköping SE-58183, Sweden
| | - Ragnhildur Bergthorsdottir
- Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, and
- Department of Endocrinology, Sahlgrenska University Hospital, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-40530, Sweden
| | - Gudmundur Johannsson
- Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, and
- Department of Endocrinology, Sahlgrenska University Hospital, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-40530, Sweden
| | - Emma Lindskog
- Department of Pediatrics, Institute of Clinical Sciences
| | - Mona Landin-Olsson
- Department of Endocrinology, Skåne University Hospital, Lund SE-22362, Sweden; and
| | - Maria Elfving
- Department of Pediatrics, Pediatric Endocrinology, Clinical Sciences, Lund University, Lund SE-22362, Sweden
| | - Erik Waldenström
- Department of Endocrinology, Skåne University Hospital, Lund SE-22362, Sweden; and
| | | | - Olle Kämpe
- Centre for Molecular Medicine, Department of Medicine (Solna)
- Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Karolinska Institutet, Stockholm SE-17176, Sweden
| | - Sophie Bensing
- Department of Molecular Medicine and Surgery, and
- Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Karolinska Institutet, Stockholm SE-17176, Sweden
| |
Collapse
|
2
|
Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J, Girodon F, Andréasson B. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med 2015; 26:344-7. [PMID: 25863408 DOI: 10.1016/j.ejim.2015.03.009] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2015] [Revised: 03/22/2015] [Accepted: 03/24/2015] [Indexed: 01/05/2023]
Abstract
BACKGROUND Vascular complications occurring before the diagnosis of myeloproliferative neoplasms (MPN) in 612 patients from four centers in Sweden, Denmark and France were retrospectively studied. RESULTS Vascular complications were observed in 151 (25%) of the 612 patients. Of these, 66% occurred during the two years preceding diagnosis. The majority of events were thromboembolic (95%), and included myocardial infarction (n=46), ischemic stroke (n=43), transient ischemic attack (TIA) (n=22), deep vein thrombosis/pulmonary embolism (n=19), splanchnic vein thrombosis (n=7), and peripheral embolism (n=7). Bleeding was observed in only 7 (5%) of the 151 patients with vascular events (3 with intracranial bleeding, 2 with epistaxis and 2 with gastrointestinal bleeding). Full blood counts obtained at least 3 months prior to the MPN diagnosis showed that 269 (44%) had abnormal blood values, fulfilling the diagnostic criteria for MPN. During the time from the abnormal blood test to the diagnosis of MPN, 50 patients suffered from a vascular complication. CONCLUSION We therefore conclude that a large proportion of MPN patients suffer severe thromboembolic complications prior to diagnosis. If MPN were diagnosed earlier, a large proportion of these events might be prevented. An MPN should always be suspected and ruled out in patients with unexplained elevated hematocrit, leukocyte and/or platelet counts.
Collapse
Affiliation(s)
| | - Emma Lindskog
- Uddevalla Hospital, NU Hospital Group, Uddevalla, Sweden.
| | | | - Ditte Hersby
- Roskilde University Hospital, Roskilde, Denmark.
| | - Marie Bak
- Roskilde University Hospital, Roskilde, Denmark.
| | | | | | | |
Collapse
|